ProMIS Sets Early-2027 Date for Key Alzheimer's Antibody Readout, With Funding Lasting Past It

ProMIS Neurosciences has told investors when its most important asset will face its first real test. A corporate presentation on PMN310, the company's lead antibody for early Alzheimer's disease, puts the topline readout from the Phase 1b PRECISE-AD study in the first quarter of 2027. The company also says its cash runway reaches through 2027, meaning the money on hand is meant to cover the readout.

For a clinical-stage company with no product revenue to cite, that pairing of a dated catalyst and a funded timeline is the core of the commercial story. The deck does not, however, set out what ProMIS would do after the data arrive, so any later-stage plans, partnering ambitions or additional financing needs remain unaddressed in the material summarised here.

The company describes PMN310 as aimed at toxic amyloid-beta oligomers and positions it against the safety burden of amyloid-related imaging abnormalities, known as ARIA. Context: ARIA is a side effect associated with amyloid-targeting therapies, and both Leqembi and Kisunla carry boxed warnings, the most prominent type of safety warning on a US label. Whether PMN310 can differentiate itself on that point is, by the deck's own framing, something the trial data must show.

The presentation cites blinded interim data as of 22 July 2026. Blinded figures do not separate drug from comparator, so they cannot indicate how PMN310 performs relative to control or to marketed antibodies. The summary of the deck gives no detail on what those interim figures contain, and any ARIA comparison will depend on unblinded results.